Studies have shown that cisplatin promotes the infiltration of inflammatory APCs into tumors, which express higher levels of CD70, CD80, and CD86 co-stimulatory ligands, leading to the induction and activation of tumor-specific CD8+ T cells (Beyranvand Nejad et al., 2016). Here, CD8A is linked to neoplasm.